FDA Issues 25 More Warning Letters to Telehealth Companies Over Compounded GLP-1 Marketing Claims

On June 16, 2026, the FDA posted a third wave of warning letters, 25 letters to telehealth companies, over false or misleading website claims about compounded GLP-1 products, according to Reuters reporting on the FDA letters. The letters themselves are dated June 8, 2026 and were posted on June 16, 2026.

Reuters reported that the letters covered compounded semaglutide and tirzepatide products and, in one case, a liraglutide product. No separate FDA press announcement for this wave was found in the research record, so the account of the wave rests on Reuters reporting and the FDA telehealth guidance page.

According to the reporting, the alleged violations followed a familiar pattern from earlier waves. The letters cited claims implying that compounded products were the same as FDA-approved drugs, branding that suggested the telehealth company was itself the compounder, and claims that a sourcing pharmacy or facility was FDA-approved or FDA-licensed.

The FDA also published a dedicated guidance page for telehealth companies on promoting compounded drugs. That page is the agency's own statement of what telehealth sellers should know when they promote compounded products.

A warning letter is an FDA allegation and enforcement step, not a court finding. Compounded drugs are not FDA-approved, and approval of a brand-name GLP-1 product applies only to that specific product and its labeled indication, never to compounded versions of the same molecule.